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Abstract
History hallmarks different out brakes events during the last century. Being 
caught in the in the middle of the catastrophic COVID-19 pandemic, that initiated 
in 2019 makes possible to forget other causalities. Tuberculosis makes the case. The 
pathogen has been present more than hundredth years. Relevance rest in worldwide 
prevalence, pathogen spread, treatment resistance and the need for eradication. 
Drug treatment resistance is considered as one of the criteria to prioritize a country 
in the World Health Organization’s intention to eradicate tuberculosis infection in 
the world. For decades in Latin America, including the Caribbean, there have been 
a persistent high rate of drug resistance with an overall prevalence to one or more 
drug rounds 13.0%. Approximately 30% of previously treated cases have a multi-
drug resistance. In this chapter, we intend to review the epidemiology of resistant 
tuberculosis, and the causes of resistance associated to the community of people in 
the Latin American and the Caribbean. We intend to describe the genetic response 
of Mycobacterium tuberculosis from its migratory journey throughout decades from 
areas of Europa and Asia to Latin America, its genetic transformation secondary 
to inadequate drug exposure and the characteristics of the infected host, and how 
a change in the healthcare system and tuberculosis control strategies access are 
needed to change the surge of multidrug resistance tuberculosis.
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1. Introduction
More than 100 years have been since the discovery of Mycobacterium tuberculosis (TB) 
and still continues to be one of the world’s leading causes of death by a single infectious 
organism. Despite extensive knowledge of its pathophysiology and its infectious 
characteristics, TB continues to cause great morbidity, and continue to be a signifi-
cant diagnostic challenge. But far from making the diagnosis, the true odyssey occurs 
when many patients develop an infection with resistance to available therapy.
Mycobacterium tuberculosis is a bacillus shaped, aerobic, slow growing and 
acid-fast positive staining bacteria. The organism is mostly transmitted through 
out droplets of particles suspended in the air, and inhalation by the infected host. 
Deposition of the bacteria in the tissues, especially the lungs, cause the principal 
manifestations of the disease. Most of the infected people developed a natural 
immunity by phagocytes which engulf the mycobacteria and form granulomas 
causing no clinical symptoms. This is known as latent tuberculosis. Differently, 
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around 10% of exposed people develop active infection, characterized by cavitary 
and fibrotic lung disease [1]. Immunosuppression can cause that tuberculosis bacilli 
migrate from the initial lung infection to other sites, causing extra pulmonary 
disease, which is one of the most lethal sequelae of the infection. TB can virtually 
invade any organ system and mimic other noninfectious conditions, causing to be 
a significant source of morbidity and mortality [2]. Early identification and appro-
priate treatment are the clues to obtain a satisfactory outcome.
The diagnosis of TB is done by identification of the mycobacteria in the affected 
tissue by culture or polymerase chain reaction. Once the organism is identified, 
combination antimicrobial drug therapy is started, and continued according to 
drug sensitivity. Length of treatment is determined by the site of infection and the 
immunologic status of the host, as well as the drug sensitivity of the organism.
Before the end of the first half of the 20th century, antimicrobial medications 
for Tuberculosis were discovered, following by the use of combination drug therapy 
as its principal management [3]. Around 1970s, the use of medications as Isoniazid 
and Rifampin were established as the principal core of treatment that participates 
in addition to other drugs for treatment of tuberculosis. The combination with 
other drugs allowed to decrease length of therapy to around 6 months [3]. After 
more than 50 years, new drugs for tuberculosis have been approved in 2019. The 
assemblance of previous known drugs and new ones is the pivotal therapy for the 
infection, including those with resistance to one or more medications (Figure 1).
In between the amaze and current focus in the catastrophic pandemic of Covid-
19, we tend to forget that a year before in 2018, M. tuberculosis infected more than 
10 million people, with 1.5 million people dying from the disease [1]. Despite being 
TB a well-known disease, it is suspected that more than one third of the cases did 
not receive adequate treatment due to lack of diagnosis and lack of resources [1]. 
Besides the direct poor outcome in the individual patient, the absence of an appro-
priate treatment increase the risk of developing drug resistance, facilitates altera-
tions in the genealogy, and favors poor outcomes in morbidity and mortality. Thus, 
drug resistance is considered a significant menace to populations of high prevalence 
of disease, and an important set back to eradicate the infection.
Genealogy is described as the study of the history of a specific descendance 
and how we can follow the different lineages of a family or group. Throughout 
exposure to drugs, TB has developed the capability of resist antimicrobial therapy, 
which have evolved in strains that survive beyond those which are sensitive to 
medications, creating those drug resistant populations of mycobacteria. Current 
technologies, allow the identification of TB strains with drug resistance using DNA 
tests which detect genetic mutations to different drugs is less than 48 hours [4]. 
Also, gene sequencing studies have allowed to follow the lineage of TB in different 
areas of Latin America. Using specific “gene markers” and mutations detected by 
Figure 1. 
2016 WHO Drug Therapy Groups Tuberculosis.
3
Genealogy of Resistant Tuberculosis in Latin America and the Caribbean until 2020
DOI: http://dx.doi.org/10.5772/intechopen.96280
polymerase chain reactions, the populations of mycobacteria are identified and 
characterized in different territories [5]. Those genetically identified strains are 
compared to TB strains in Europa and other continents, and are studied along with 
migration patterns from those regions, establishing familiar origins.
2. Definition of drug resistance and causes
As mentioned above, the most common therapy for tuberculosis originated from 
1970s, which consist in a combination of Isoniazid (INH) and Rifampin (RIF). 
Adding Ethambutol (EMB) and Pyrazinamide (PZA) can shorten the length of 
therapy. The first two drugs are considered as the firs line therapy for tuberculosis 
(Figure 1). These are the basic definitions of drug resistant TB:
• Drug-resistant tuberculosis is when TB remains unaffected to at least one 
anti-tuberculosis drug.
• Mono drug resistance refers to an infection with resistance to one of the first 
line agents.
• Poly-drug resistant TB occurs when there is resistance to two or more anti-TB 
drugs but not to both INH and Rifampicin simultaneously.
• Multidrug-resistant tuberculosis (MDR-TB) occurs when resistance 
occurs in more than one antimicrobial drug, or at least isoniazid (INH) and 
rifampin (RIF).
• Extensively drug resistance tuberculosis (XDR-TB): The extreme case of 
resistance, in which TB is resistant to at least one drug in each group in the sec-
ond line therapy groups (see Figure 1, groups A to D), besides being resistant 
to first line therapy.
• For the purpose of this chapter, we will refer and discuss mainly to the multi-
drug resistant tuberculosis (MDR-TB).
3. Drug resistance
The development of drug resistance of tuberculosis seems to be secondary to 
a mutation process of a chromosome that can cause that a specific population of 
mycobacteria develops a “phenotypic resistance” to a certain drug. That muta-
tion can be cause an alteration in the drug transport in the cell membrane of the 
mycobacteria, or the increase in production of an enzyme that metabolize and 
cause incapacity of the treatment drug. When those mycobacterias are exposed to 
either inappropriate antimicrobial therapy, inappropriate length of treatment, poor 
quality or low dose of medications, or lack of combination therapy, confers to the 
resistant bacteria a survival advantage that allows a “genetic” transformation which 
is transmitted over other nonresistant strains [6].
The common use of more than one drug to treat TB resulted from initial studies 
that showed a progressive increased in mycobacterial populations with resistance 
in sputum cultures from patients treated only with streptomycin. Combining 
para-aminosalicylic acid with streptomycin in a clinical trial showed a more than 7 
to 8 times decrease in the rate of resistance to streptomycin [7]. With the eventual 
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discovery of the efficacy of other antimicrobial drugs against tuberculosis, multiple 
other combination therapy studies were done, until current regimes were obtained. 
When done adequately, many countries have been able to eradicate tuberculosis 
using direct observe therapy programs monitoring adequate compliance with 
medications including dosing and regimes.
Each drug against TB has a specific mechanism to cause the bactericidal or 
bacteriostatic effect on the microorganism. In the case of INH, a specific enzyme 
is activated by the antibiotic inside the cell to inhibits the production of myco-
litic acid, which is integral part of the mycobacterial cell wall [8]. For example, 
Rifampin inhibits the proliferation of ribonucleic acid, which inhibits genetic 
material replication and bacterial proliferation.
Mutations that impede Rifampin to inhibit the synthesis of RNA cause drug 
resistance. In the case of IZH, the drug needs an activation of its initial pro-drug 
state. A defect in the enzyme that metabolize IZH to its active state will cause 
resistance to IZH. Rifampin resistance is considered rare and usually occurs con-
comitantly with resistant of other drugs. This makes the resistance of Rifampin a 
marker of multiple drug resistance (MDR-TB) [8]. Other drugs as PZA and EMB 
also function inhibiting the formation of other components of the cell wall, and 
resistance occurs by mechanism similar to IZH and RIF.
The characteristics of the infected host also can influence in the developing of 
drug resistance. Immunosuppression allows the mycobacteria to survive the host 
immunological reaction and proceed to active disease. This can cause popula-
tion spreading of disease and further dissemination of mycobacterial strains. 
Immunosuppression include the use of chemotherapy, immunotherapy and anti-
inflammatory medications, patients with severe and uncontrolled diabetes mellitus 
and human Immunodeficiency virus infection (HIV).
Human Immunodeficiency virus infection have been particularly linked to the 
development of MDR-TB. In patients with HIV there are many factors contributing 
to the development of drug resistance. Those factors include: the rapid progression 
of HIV with concomitant tuberculosis infection, poor absorption and interac-
tions between HIV and tuberculosis drugs, and exposure to high risk of resistance 
populations as other resistant tuberculosis patients, intravenous drug and alcohol 
users and other patients with poor compliance to medications [9].
Data regarding Diabetes mellitus and development of drug resistance to 
tuberculosis have been variable. However a recent metanalysis published in 2018, 
showed significant association between DM and MDR-TB, which was not linked 
to the degree of economic development of the country. Again, the degree of 
immunosuppression secondary to uncontrolled diabetes is related to the possibility 
of developing active disease and infection spreading in the population. The same 
case occurs with other type of chronic immunosuppression as patients of chemo-
therapy, immunosuppressive therapy for autoimmune diseases and the chronic use 
of systemic steroids in patients with respiratory conditions as chronic obstructive 
pulmonary disease (COPD) and asthma. A publication in 2015 suggested a strong 
association of MDR-TB with COPD patients with advanced stage disease, severe 
airway obstruction and long term use of corticosteroids [10]. Also, the multiple use 
of antibiotics to treat COPD exacerbations, including fluoroquinolones, contribute 
to the risk of developing drug resistance [10].
4. Epidemiology of drug of drug resistant tuberculosis
It is known that around 4% of newly diagnosed tuberculosis patients are multi-
drug resistance [11]. From those previously treated, MDR-TB have been reported in 
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more than 20% worldwide [11]. The Global Tuberculosis Report of 2019 recognize 
more than 400,000 patients with drug resistance TB [1]. In 2019, before Covid-19 
became the global threat that we have been seen now, MDR-TB continued to be a 
public health crisis with 206,030 patients reported with MDR-TB around the world, 
a 10% increase from numbers reported in 2018 [12]. According to the World Health 
Organization, the countries with more MDR-TB burden are India, China and Russia.
In America, Center and South American as the areas with more MDR-TB 
burden. Around 3% of the total tuberculosis cases reported in the world are from 
American territories [5]. South America was the region with more incidence 
of tuberculosis with 46.2 per 100,000 of population, mostly from areas of the 
Caribbean and Central America [5]. The data regarding each region has been vari-
able, but Brazil, Peru, and Mexico have almost half of the cases of Latin America 
[13]. Costa Rica, Cuba, Jamaica, Puerto Rico, and Trinidad and Tobago reported an 
incidence close to the threshold for tuberculosis elimination [5].
When talking about MDR-TB in America, previous publications signaled 
Countries as Peru, Ecuador and Brazil for most of the cases reported [14]. The 
overall prevalence of MDR-TB according to a metanalysis published in 2020 [15] 
was 13%, but it reached 28% in those patient populations previously treated cases 
for tuberculosis. The reported prevalence have been increased when studied from 
period ending in 2010 to 2018 [15]. Colombia, Mexico, and Dominican Republic, in 
data published in 2020, have a reported overall prevalence of MDR-TB of around 
20% [15], with more of 30% of attributed to a previous failed or inadequate 
treatment. In the United States, data reports around 1% of MDR-TB of the total 
of tuberculosis patients identified [16], being considered a low burden country 
for MDR-TB.
In the Caribbean, as mentioned above Dominican Republic is the country with 
more prevalence of MDR-TB reported. However, data regarding the number of 
cases in many of the territories of the Caribbean is scarce. Haiti was also identified 
as a high burden MDR-TB area, with around 306 cases per 100,000 of population in 
2014 [17].
5.  Causes of drug resistant in Latin American and the Caribbean 
territories
Phenotypic resistance of the mycobacteria due to lack of appropriate treatment 
is considered one of the reasons for which the rate of MDR-TB has not decreased 
through the years. However, throughout genetic sequencing studies, the genealogy 
of tuberculosis origin in Latin America has been study. In the case of MDR-TB, 
considering data that suggest that horizontal gene transfers are nonexistent 
between M. tuberculosis bacteria [5], is genetic transformation probably the cause 
of widely spread of resistance between the above mentioned populations. In this 
case, genetic transformation refers to the survival advantage of those strains of 
mycobacteria with acquired resistance to certain drugs over others more sensitive 
bacterial population. This occurs when mycobacteria are exposed to inadequate 
therapy, including low quality and dose of medications, the lack of use of combina-
tion therapy, intermittent use of medications or inadequate length of therapy. Data 
from Peru during the 90’s decade, where they stablished Direct Observe Therapy 
(DOT), showed a significant decrease in the prevalence of MDR-TB [14], consistent 
with this theorem of phenotypic resistance that culminate in genetic transformation 
of the mycobacteria in the population.
A recent publication about the genetic epidemiology of tuberculosis in Latin 
America discuss how the migratory patterns from Europa and Asia have define 
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the genealogy of the mycobacteria in those territories [5]. For example, Peru 
showed a large number of tuberculosis strains very similar to those found on 
Beijing, compatible with a well-known historical Chinese migration to that coun-
try. Those genetic origins allow the mycobacteria to have different virulence, 
increasing its capability to survive and being transmitted between hosts. Those 
mycobacteria have developed the capability to survive the immune response 
of the host, the external environment in the droplet and particles transmitted, 
and an increase capability to cause active disease, increasing the probability of 
population spread. This environmental resistance conferred to those genetically 
more fitted strains has been associated with an increased risk of developing drug 
resistance [5].
Again, data is scarce in the specific prevalence of MDR-TB in all regions of the 
Caribbean. However extremely high incidence of tuberculosis in territories such 
as Haiti and Dominican Republic have overlap with a high rate of co-infection 
with Human Immunodeficiency Virus (HIV). The degree of immunosuppression 
contribute to the developing of active disease, population spreading of infection, 
and dissemination of selected tuberculosis strains, including those which are drug 
resistant. High prevalence of other conditions such as COPD and diabetes also 
contribute to the tuberculosis spread and the development of drug resistant infec-
tion. In addition, the limited access and poor quality of health care services, malnu-
trition, poverty and underprivilege living conditions are associated to the spread of 
tuberculosis throughout populations [18]. All of those factors are highly prevalent 
in the Caribbean countries.
6. Conclusion
Limited healthcare and economic resources, inadequate exposure to anti tuber-
culosis drug regimens and specific characteristics of the infected host, have paved 
the long way to the genetic inheritance of resistant strains of tuberculosis to develop 
and propagate in this side of the world. Migratory patterns from Europa and Asia to 
the Latin American territories have brought tuberculosis strains with genes capable 
of resists specific drugs, but it has been the inadequate use of medication and the 
exposures in these lands that have allowed the genetic transformation of bacteria 
in the populations. As Peru did in decade of 1990, establishing direct observa-
tion therapy programs help significatively to decrease the prevalence of MDR-TB 
strains in the population [14]. Also, prevention of TB spread with rapid diagnosis 
and screening in high risk populations is a pivotal way to decrease the surge of new 
cases. The global use of the new genetic rapid tests for detecting drug resistant 
strains of TB [4] is another way for eradication of MDR-TB. Most important, is 
to increase population’s access to appropriate therapy for those with sensitive and 
resistant TB infections.
The reach for better healthcare systems, population awareness, programs for 
better screening and assurance of adequate treatment for tuberculosis patients will 
be the only infallible tool to decrease the rate of MDR-TB infections and the way to 
achieve eradication.
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